当前位置： SCI文献检索 > LEUKEMIA期刊下所有文献 > Identification of circulating CD10 positive T cells in angioimmunoblastic T-cell lymphoma.

Identification of circulating CD10 positive T cells in angioimmunoblastic T-cell lymphoma.

Abstract：

:In most cases of lymphomas with blood dissemination, the careful cytological analysis of peripheral blood smears provides a rapid orientation to diagnosis, even if the final subtyping is achieved by histology and eventually other techniques. Here, we evaluated if the analysis of blood smears may suggest the blood dissemination of angioimmunoblastic T-cell lymphoma (AITL) and if CD10 expression on neoplastic T cells, as recently reported on AITL, may contribute to the diagnosis. In all, 11 lymph nodes and six peripheral blood samples from 12 patients with AITL were studied using four-colour flow cytometry associated to histological, cytological and molecular data. According to previous results, a fraction of T cells expressed CD10 in 10/11 lymph nodes. Interestingly, all blood smears showed atypical lymphoid cells and a fraction of T cells expressed CD10 with a mean percentage of 18.75% (range 5.00-47.00%), regardless of lymphocytosis level and of rate of CD10 T cells in corresponding lymph node. In contrast, in all control samples (100), none CD10-positive T cell was identified. This is to our knowledge the first description of circulating CD10 neoplastic T cells in AITL. Therefore, they ought to be explored in further studies when aggressive lymphoma, in particular with lymphopenia and circulating atypical cells, is suspected.

journal_name

Leukemia

journal_title

Leukemia

authors

Baseggio L,Berger F,Morel D,Delfau-Larue MH,Goedert G,Salles G,Magaud JP,Felman P

doi

10.1038/sj.leu.2404013

subject

Has Abstract

pub_date

2006-02-01 00:00:00

pages

296-303

issue

2

eissn

0887-6924

issn

1476-5551

pii

2404013

journal_volume

20

pub_type

杂志文章

相关文献

LEUKEMIA文献大全
  • In vivo thrombin and plasmin activities in patients with acute promyelocytic leukemia (APL): effect of all-trans retinoic acid (ATRA) therapy.

    abstract：:APL-associated hemostasis disorders result from at least two distinct mechanisms due to the release of procoagulant activities and plasminogen activators from the leukemic cells. These two mechanisms (thrombin activation and plasmin activation) may cleave the fibrinogen molecule, but their respective roles in low fibr...

    journal_title：Leukemia

    pub_type： 杂志文章

    doi：

    authors： Dombret H,Scrobohaci ML,Daniel MT,Micléa JM,Castaigne S,Chomienne C,Fenaux P,Degos L

    更新日期：1995-01-01 00:00:00

  • Sensitive and reproducible detection of occult disease in patients with follicular lymphoma by PCR amplification of t(14;18) both pre- and post-treatment.

    abstract：:The t(14;18) chromosomal translocation occurs in most follicular non-Hodgkin's lymphomas and places the Bcl-2 gene on chromosome 18q21 into the immunoglobulin JH region on chromosome 14q32. This translocation can be exploited to detect clonal malignant cells bearing this genetic alteration. A polymerase chain reaction...

    journal_title：Leukemia

    pub_type： 杂志文章

    doi：

    authors： Berinstein NL,Jamal HH,Kuzniar B,Klock RJ,Reis MD

    更新日期：1993-01-01 00:00:00

  • Next-generation XPO1 inhibitor shows improved efficacy and in vivo tolerability in hematological malignancies.

    abstract：:The nuclear export receptor, Exportin 1 (XPO1), mediates transport of growth-regulatory proteins, including tumor suppressors, and is overactive in many cancers, including chronic lymphocytic leukemia (CLL), acute myeloid leukemia (AML) and aggressive lymphomas. Oral selective inhibitor of nuclear export (SINE) compou...

    journal_title：Leukemia

    pub_type： 杂志文章

    doi：10.1038/leu.2016.136

    authors： Hing ZA,Fung HY,Ranganathan P,Mitchell S,El-Gamal D,Woyach JA,Williams K,Goettl VM,Smith J,Yu X,Meng X,Sun Q,Cagatay T,Lehman AM,Lucas DM,Baloglu E,Shacham S,Kauffman MG,Byrd JC,Chook YM,Garzon R,Lapalombella R

    更新日期：2016-12-01 00:00:00

  • Impairing MLL-fusion gene-mediated transformation by dissecting critical interactions with the lens epithelium-derived growth factor (LEDGF/p75).

    abstract：:The lens epithelium-derived growth factor (LEDGF/p75) tethers the mixed-lineage leukemia (MLL1) protein complex to chromatin. Likewise, LEDGF/p75 tethers the HIV-1 pre-integration complex to chromatin. We previously demonstrated that expression of the C-terminal fragment fused to enhanced green fluorescent protein (eG...

    journal_title：Leukemia

    pub_type： 杂志文章

    doi：10.1038/leu.2013.10

    authors： Méreau H,De Rijck J,Cermáková K,Kutz A,Juge S,Demeulemeester J,Gijsbers R,Christ F,Debyser Z,Schwaller J

    更新日期：2013-06-01 00:00:00

  • Decision analysis of allogeneic hematopoietic stem cell transplantation for patients with myelodysplastic syndrome stratified according to the revised International Prognostic Scoring System.

    abstract：:Allogeneic hematopoietic stem cell transplantation (allo-SCT) represents the only curative treatment for patients with myelodysplastic syndrome (MDS), but involves non-negligible morbidity and mortality. Crucial questions in clinical decision-making include the definition of optimal timing of the procedure and the ben...

    journal_title：Leukemia

    pub_type： 杂志文章

    doi：10.1038/leu.2017.88

    authors： Della Porta MG,Jackson CH,Alessandrino EP,Rossi M,Bacigalupo A,van Lint MT,Bernardi M,Allione B,Bosi A,Guidi S,Santini V,Malcovati L,Ubezio M,Milanesi C,Todisco E,Voso MT,Musto P,Onida F,Iori AP,Cerretti R,Grillo

    更新日期：2017-11-01 00:00:00

  • The murine long-term multi-lineage renewal marrow stem cell is a cycling cell.

    abstract：:Prevailing wisdom holds that hematopoietic stem cells (HSCs) are predominantly quiescent. Although HSC cycle status has long been the subject of scrutiny, virtually all marrow stem cell research has been based on studies of highly purified HSCs. Here we explored the cell cycle status of marrow stem cells in un-separat...

    journal_title：Leukemia

    pub_type： 杂志文章

    doi：10.1038/leu.2013.252

    authors： Goldberg LR,Dooner MS,Johnson KW,Papa EF,Pereira MG,Del Tatto M,Adler DM,Aliotta JM,Quesenberry PJ

    更新日期：2014-04-01 00:00:00

  • TP53 deficiency permits chromosome abnormalities and karyotype heterogeneity in acute myeloid leukemia.

    abstract：:Abnormal karyotypes are common in cancer cells and frequently observed in acute myeloid leukemia (AML), in which complex karyotype aberrations are associated with poor prognosis. How exactly abnormal karyotypes arise and are propagated in AML is unclear. TP53 mutations and deletions are frequent in complex karyotype A...

    journal_title：Leukemia

    pub_type： 杂志文章

    doi：10.1038/s41375-019-0550-5

    authors： Cazzola A,Schlegel C,Jansen I,Bochtler T,Jauch A,Krämer A

    更新日期：2019-11-01 00:00:00

  • Current status of reduced-intensity allogeneic stem cell transplantation using alternative donors.

    abstract：:The optimal donor for a patient undergoing reduced-intensity stem cell transplantation remains a human leukocyte antigen (HLA)-matched relative. Alternative donors such as matched unrelated donors (MUDs), mismatched related donors (haploidentical), or unrelated umbilical cord blood (UCB) units have emerged as options ...

    journal_title：Leukemia

    pub_type： 杂志文章,评审

    doi：10.1038/sj.leu.2404932

    authors： Chen YB,Spitzer TR

    更新日期：2008-01-01 00:00:00

  • In vitro responsiveness to interleukins and theophylline of CD16+, CD56- natural killer cells in a patient with chronic granular lymphocyte disorder.

    abstract：:We report here the case of a 55-year-old patient with chronic granular lymphocyte disorder associated with moderate neutropenia. The majority of peripheral blood lymphocytes displayed a CD3-, CD8-, CD16+, CD56(NKH1)- phenotype. The patient's cells showed high spontaneous cytotoxic activity against K562 targets and dev...

    journal_title：Leukemia

    pub_type： 杂志文章

    doi：

    authors： Bayle C,Vitté-Mony I,Lang P,Pico J,Hercend T,Bertoglio J

    更新日期：1992-05-01 00:00:00

  • Long-term results of St Jude Total Therapy Studies 11, 12, 13A, 13B, and 14 for childhood acute lymphoblastic leukemia.

    abstract：:We analyzed the long-term outcome of 1011 patients treated in five successive clinical trials (Total Therapy Studies 11, 12, 13A, 13B, and 14) between 1984 and 1999. The event-free survival improved significantly (P=0.003) from the first two trials conducted in the 1980s to the three more recent trials conducted in th...

    journal_title：Leukemia

    pub_type： 临床试验,杂志文章

    doi：10.1038/leu.2009.252

    authors： Pui CH,Pei D,Sandlund JT,Ribeiro RC,Rubnitz JE,Raimondi SC,Onciu M,Campana D,Kun LE,Jeha S,Cheng C,Howard SC,Metzger ML,Bhojwani D,Downing JR,Evans WE,Relling MV

    更新日期：2010-02-01 00:00:00

  • Leukemic dendritic cells generated in the presence of FLT3 ligand have the capacity to stimulate an autologous leukemia-specific cytotoxic T cell response from patients with acute myeloid leukemia.

    abstract：:It has been proposed that adoptive immunotherapy, for the treatment of relapsed AML, with cytotoxic T lymphocytes which show a relative specificity for the leukemic cells may have the advantage of maximizing the beneficial anti-leukemic effect whilst minimizing the probability of graft-versus-host disease. In this stu...

    journal_title：Leukemia

    pub_type： 杂志文章

    doi：10.1038/sj.leu.2402013

    authors： Woiciechowsky A,Regn S,Kolb HJ,Roskrow M

    更新日期：2001-02-01 00:00:00

  • NOTCH1 mutations are associated with high CD49d expression in chronic lymphocytic leukemia: link between the NOTCH1 and the NF-κB pathways.

    abstract：:In chronic lymphocytic leukemia (CLL), stabilizing mutations of NOTCH1, affecting up to 10-15% of cases, have been associated to poor prognosis, disease progression and refractoriness to chemotherapy. NOTCH1 mutations are significantly overrepresented in trisomy 12 CLL, a disease subset frequently expressing CD49d, th...

    journal_title：Leukemia

    pub_type： 杂志文章

    doi：10.1038/leu.2017.296

    authors： Benedetti D,Tissino E,Pozzo F,Bittolo T,Caldana C,Perini C,Martorelli D,Bravin V,D'Agaro T,Rossi FM,Bomben R,Santinelli E,Zaja F,Pozzato G,Chiarenza A,Di Raimondo F,Del Poeta G,Rossi D,Gaidano G,Dal Bo M,Gattei V

    更新日期：2018-03-01 00:00:00

  • Genomic approaches to small molecule discovery.

    abstract：:With the sequencing of the human genome and the development of new genomic technologies, biomedical discovery has been transformed. The applications of these new approaches are ever-expanding from disease classification, to identification of new targets, to outcome prediction. A logical next step is the integration of...

    journal_title：Leukemia

    pub_type： 杂志文章,评审

    doi：10.1038/leu.2009.29

    authors： Stegmaier K

    更新日期：2009-07-01 00:00:00

  • Importance of MEK-1/-2 signaling in monocytic and granulocytic differentiation of myeloid cell lines.

    abstract：:Activation of the MEK/ERK/MAP kinase signaling pathway promotes the proliferation and survival of hematopoietic cells. The kinases MEK-1, MEK-2, ERK-1/MAPK and ERK-2/MAPK are activated by phosphorylation at specific sites, and these events can be monitored using phospho-specific antibodies. In this report we examined ...

    journal_title：Leukemia

    pub_type： 杂志文章

    doi：10.1038/sj.leu.2402400

    authors： Miranda MB,McGuire TF,Johnson DE

    更新日期：2002-04-01 00:00:00

  • Rates of peripheral arterial occlusive disease in patients with chronic myeloid leukemia in the chronic phase treated with imatinib, nilotinib, or non-tyrosine kinase therapy: a retrospective cohort analysis.

    abstract：:Peripheral arterial occlusive disease (PAOD) occurs in patients with chronic phase chronic myeloid leukemia (CML-CP) treated with tyrosine kinase inhibitors (TKIs). The risk of developing PAOD on TKI therapy is unknown and causality has not been established. Patients with CML-CP from three randomized phase III studies...

    journal_title：Leukemia

    pub_type： 杂志文章

    doi：10.1038/leu.2013.69

    authors： Giles FJ,Mauro MJ,Hong F,Ortmann CE,McNeill C,Woodman RC,Hochhaus A,le Coutre PD,Saglio G

    更新日期：2013-06-01 00:00:00

  • Phase I/II trial of the oral regimen ixazomib, pomalidomide, and dexamethasone in relapsed/refractory multiple myeloma.

    abstract：:In this phase I/II trial, a triplet regimen of ixazomib (Ixa: 3 or 4 mg), pomalidomide (Pom: 4 mg), and dexamethasone (Dex: 40 mg) was administered to 32 lenalidomide-refractory multiple myeloma (MM) patients; 31 were evaluable for response and toxicity. At dose level 1 (DL1, 3 mg Ixa), 1/3 patients experienced grade ...

    journal_title：Leukemia

    pub_type： 杂志文章

    doi：10.1038/s41375-018-0038-8

    authors： Krishnan A,Kapoor P,Palmer JM,Tsai NC,Kumar S,Lonial S,Htut M,Karanes C,Nathwani N,Rosenzweig M,Sahebi F,Somlo G,Duarte L,Sanchez JF,Auclair D,Forman SJ,Berdeja JG

    更新日期：2018-07-01 00:00:00

  • Validity of the in vitro system as a correlate of the in vivo model of RadLV lymphomagnesis.

    abstract：:Adult BL/6 mice are highly sensitive to lymphomagnesis by the radiation leukemia virus variant A-RadLV (80-100% T-cell lymphoma incidence after a latency of 70-110 days). This study shows that the in vivo elimination of T-cell subsets (including suppressor and cytotoxic T-cells) achieved by the repeated administration...

    journal_title：Leukemia

    pub_type： 杂志文章

    doi：

    authors： Haran-Ghera N,Peled A

    更新日期：1991-06-01 00:00:00

  • Genetic predisposition for multiple myeloma.

    abstract：:Multiple myeloma (MM) is the second most common blood malignancy. Epidemiological family studies going back to the 1920s have provided evidence for familial aggregation, suggesting a subset of cases have an inherited genetic background. Recently, studies aimed at explaining this phenomenon have begun to provide direct...

    journal_title：Leukemia

    pub_type： 杂志文章,评审

    doi：10.1038/s41375-019-0703-6

    authors： Pertesi M,Went M,Hansson M,Hemminki K,Houlston RS,Nilsson B

    更新日期：2020-03-01 00:00:00

  • NOTCH inhibition and glucocorticoid therapy in T-cell acute lymphoblastic leukemia.

    abstract：:Inhibition of NOTCH1 signaling with gamma-secretase inhibitors (GSIs) has been proposed as a molecularly targeted therapy in T-cell acute lymphoblastic leukemia (T-ALL). However, GSIs seem to have limited antileukemic activity in human T-ALL and are associated with severe gastrointestinal toxicity resulting from inhib...

    journal_title：Leukemia

    pub_type： 杂志文章,评审

    doi：10.1038/leu.2009.75

    authors： Real PJ,Ferrando AA

    更新日期：2009-08-01 00:00:00

  • Acute myeloid leukemia (AML) having evolved from essential thrombocythemia (ET): distinctive chromosome abnormalities in patients treated with pipobroman or hydroxyurea.

    abstract：:ET is a chronic myeloproliferative disorder rarely evolving into AML, sometimes preceded by a myelodysplastic syndrome (MDS). Such transformations mostly occur in patients treated with radiophosphorous ((32)P) or alkylating agents, especially busulfan. Recently, concern has also arisen about the long-term safety of hy...

    journal_title：Leukemia

    pub_type： 杂志文章

    doi：10.1038/sj.leu.2402638

    authors： Bernasconi P,Boni M,Cavigliano PM,Calatroni S,Brusamolino E,Passamonti F,Volpe G,Pistorio A,Giardini I,Rocca B,Caresana M,Lazzarino M,Bernasconi C

    更新日期：2002-10-01 00:00:00

  • Two acute monocytic leukemia (AML-M5a) cell lines (MOLM-13 and MOLM-14) with interclonal phenotypic heterogeneity showing MLL-AF9 fusion resulting from an occult chromosome insertion, ins(11;9)(q23;p22p23).

    abstract：:We describe two new human leukemia cell lines, MOLM-13 and MOLM-14, established from the peripheral blood of a patient at relapse of acute monocytic leukemia, FAB M5a, which had evolved from myelodysplastic syndrome (MDS). Both cell lines express monocyte-specific esterase (MSE) and MLL-AF9 fusion mRNA. Gene fusion is...

    journal_title：Leukemia

    pub_type： 杂志文章

    doi：10.1038/sj.leu.2400768

    authors： Matsuo Y,MacLeod RA,Uphoff CC,Drexler HG,Nishizaki C,Katayama Y,Kimura G,Fujii N,Omoto E,Harada M,Orita K

    更新日期：1997-09-01 00:00:00

  • Resistance to apoptotic cell death in a drug resistant T cell leukaemia cell line.

    abstract：:In this study, we investigated the responses of the T cell leukaemia cell line, CCRF-CEM, and a vincristine-resistant subline, CEM/VCR R, to the induction of cell death by serum withdrawal. This treatment was used to overcome any contribution of P-glycoprotein-mediated drug resistance to the responses of the CEM/VCR R...

    journal_title：Leukemia

    pub_type： 杂志文章

    doi：

    authors： Geyp M,Ireland CM,Pittman SM

    更新日期：1996-03-01 00:00:00

  • Correction: Flow cytometric detection of leukemic blasts in cerebrospinal fluid predicts risk of relapse in childhood acute lymphoblastic leukemia: a Nordic Society of Pediatric Hematology and Oncology study.

    abstract：:An amendment to this paper has been published and can be accessed via a link at the top of the paper. ...

    journal_title：Leukemia

    pub_type： 已发布勘误

    doi：10.1038/s41375-020-0821-1

    authors： Thastrup M,Marquart HV,Levinsen M,Grell K,Abrahamsson J,Albertsen BK,Frandsen TL,Harila-Saari A,Lähteenmäki PM,Niinimäki R,Pronk CJ,Ulvmoen A,Vaitkevičienė G,Taskinen M,Schmiegelow K,Nordic Society of Pediatric Hematology a

    更新日期：2020-10-01 00:00:00

  • Gene therapy against retroviral diseases.

    abstract：:Eventually, gene therapy may be a valid option for chronic viral infections, including retroviral infections. Human retroviral diseases fit two categories: (1) those that result from a monoclonal outgrowth of a human T-cell leukemia virus type I (HTLV-I)-infected cell, as in the case of adult T cell leukemia (ATL); an...

    journal_title：Leukemia

    pub_type： 杂志文章,评审

    doi：

    authors： Essex M,Matsuda Z,Yu X,Lee TH

    更新日期：1995-10-01 00:00:00

  • Incomplete DJH rearrangements of the IgH gene are frequent in multiple myeloma patients: immunobiological characteristics and clinical implications.

    abstract：:DH-JH rearrangements of the Ig heavy-chain gene (IGH) occur early during B-cell development. Consequently, they are detected in precursor-B-cell acute lymphoblastic leukemias both at diagnosis and relapse. Incomplete DJH rearrangements have also been occasionally reported in mature B-cell lymphoproliferative disorders...

    journal_title：Leukemia

    pub_type： 杂志文章

    doi：10.1038/sj.leu.2402964

    authors： González D,Balanzategui A,García-Sanz R,Gutiérrez N,Seabra C,van Dongen JJ,González M,San Miguel JF

    更新日期：2003-07-01 00:00:00

  • Laying the foundation for genomically-based risk assessment in chronic myeloid leukemia.

    abstract：:Outcomes for patients with chronic myeloid leukemia (CML) have substantially improved due to advances in drug development and rational treatment intervention strategies. Despite these significant advances there are still unanswered questions on patient management regarding how to more reliably predict treatment failur...

    journal_title：Leukemia

    pub_type： 杂志文章,评审

    doi：10.1038/s41375-019-0512-y

    authors： Branford S,Kim DDH,Apperley JF,Eide CA,Mustjoki S,Ong ST,Nteliopoulos G,Ernst T,Chuah C,Gambacorti-Passerini C,Mauro MJ,Druker BJ,Kim DW,Mahon FX,Cortes J,Radich JP,Hochhaus A,Hughes TP,International CML Foundation Ge

    更新日期：2019-08-01 00:00:00

  • Characterization of an interleukin-2 dependent human leukemic cell line, PER-315, with an immature T cell phenotype which does not express the tac antigen.

    abstract：:Cell line PER-315 was established from a bone marrow sample of a 5-year-old boy diagnosed with acute lymphoblastic leukemia (ALL) of T cell lineage. PER-315 cells express the surface markers present on immature thymocytes, express cytoplasmic CD3, and their growth is dependent on interleukin-2 (IL-2). Hence, this cell...

    journal_title：Leukemia

    pub_type： 杂志文章

    doi：

    authors： Kees UR,Ford J,Ranford PR,Dawson VM

    更新日期：1990-04-01 00:00:00

  • BIOMED-I concerted action report: flow cytometric immunophenotyping of precursor B-ALL with standardized triple-stainings. BIOMED-1 Concerted Action Investigation of Minimal Residual Disease in Acute Leukemia: International Standardization and Clinical Ev

    abstract：:The flow cytometric detection of minimal residual disease (MRD) in precursor-B-acute lymphoblastic leukemias (precursor-B-ALL) mainly relies on the identification of minor leukemic cell populations that can be discriminated from their normal counterparts on the basis of phenotypic aberrancies observed at diagnosis. Th...

    journal_title：Leukemia

    pub_type： 杂志文章

    doi：10.1038/sj.leu.2402150

    authors： Lucio P,Gaipa G,van Lochem EG,van Wering ER,Porwit-MacDonald A,Faria T,Bjorklund E,Biondi A,van den Beemd MW,Baars E,Vidriales B,Parreira A,van Dongen JJ,San Miguel JF,Orfao A,BIOMED-I.

    更新日期：2001-08-01 00:00:00

  • Down's syndrome in childhood acute lymphoblastic leukemia: clinical characteristics and treatment outcome in four consecutive BFM trials. Berlin-Frankfurt-Münster Group.

    abstract：:Clinical characteristics, treatment response and outcome were evaluated in children with Down's syndrome (DS) and acute lymphoblastic leukemia (ALL) as compared to other children with ALL (NDS). Sixty-one DS and 4049 NDS patients, receiving intensive antileukemic treatment during four consecutive trials (ALL-BFM 81, 8...

    journal_title：Leukemia

    pub_type： 杂志文章

    doi：10.1038/sj.leu.2400989

    authors： Dördelmann M,Schrappe M,Reiter A,Zimmermann M,Graf N,Schott G,Lampert F,Harbott J,Niemeyer C,Ritter J,Dörffel W,Nessler G,Kühl J,Riehm H

    更新日期：1998-05-01 00:00:00

  • Treatment results of three consecutive Brazilian cooperative childhood ALL protocols: GBTLI-80, GBTLI-82 and -85. ALL Brazilian Group.

    abstract：:The Brazilian Cooperative Group for Treatment of Childhood Acute Lymphocytic Leukemia (GBTLI) has started clinical activities trials in 1980. Three consecutive multicenter studies in children with unprevious treated ALL have been completed including 994 patients. The first GBTLI-80 accrued 203 children from 1980 to 19...

    journal_title：Leukemia

    pub_type： 临床试验,杂志文章,多中心研究,随机对照试验

    doi：

    authors： Brandalise S,Odone V,Pereira W,Andrea M,Zanichelli M,Aranega V

    更新日期：1993-08-01 00:00:00